venBio

News

Home News

News

2019
17APR
Turning Point Therapeutics prices IPO at $18, the high end of the range
posted by admin in Latest News

Read More
2019
27MAR
Precision BioSciences Announces Pricing of Initial Public Offering
posted by admin in Latest News

Read More
2019
12FEB
Harmony Biosciences Announces File Acceptance Of Its New Drug Application For Pitolisant
posted by admin in Latest News

Read More
2018
12DEC
Akero Therapeutics Announces $70 Million in New Financing
posted by admin in Latest News

Read More
2018
06DEC
Impel NeuroPharma Closes $67.5 Million Series D Financing
posted by admin in Latest News

Read More
2018
27NOV
Precision BioSciences Receives FDA Authorization to Initiate Clinical Study of Gene Edited Cancer Immunotherapy
posted by admin in Latest News

Read More
2018
07NOV
ALX Oncology Presents Updated Data from ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors
posted by admin in Latest News

Read More
2018
19OCT
TP Therapeutics Completes $80 Million Mezzanine Financing Co-Led by Foresite Capital and venBio Partners
posted by admin in Latest News

Read More
2018
25JUN
Akero Therapeutics Closes $65 Million Series A Financing to Advance New Treatments for Serious Metabolic Diseases
posted by admin in Latest News

Read More
2018
17APR
TLR9 Agonist CMP-001-Pembrolizumab Combination Shows Early Efficacy in Patients With Metastatic Melanoma Resistant to Anti-PD-1
posted by admin in Latest News

Read More
2018
24JAN
Menlo Therapeutics Inc. Announces Pricing of Initial Public Offering of Common Stock
posted by admin in Latest News

Read More
2018
04JAN
Neurogastrx, Inc. Raises $45M Series A To Bring Lead GI Candidate Through Proof Of Concept
posted by admin in Latest News

Read More
2017
08NOV
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
posted by admin in Latest News

Read More
2017
05OCT
Harmony Biosciences Acquires US Rights To Pitolisant From Bioprojet; Raises $270 Million In Equity Financing
posted by admin in Latest News

Read More
2017
18JUL
venBio leads Series C Financing of oral once-daily Anti-Pruritus Therapy in development for Pruritus of Atopic Dermatitis, Psoriasis and Prurigo Nodularis, and for Refractory Chronic Cough
posted by admin in Latest News

Read More
2017
15JUNE
Checkmate Pharmaceuticals Secures $27 Million Series B Preferred Financing and Appoints Karen Brennan as Chief Operating Officer
posted by admin in Latest News

Read More
2017
10APR
Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for the Treatment of Advanced Solid Tumors and Lymphoma
posted by admin in Latest News

Read More
2016
02DEC
Impel NeuroPharma Announces $36M Funding to Advance Novel Drug Delivery Platform for Central Nervous System Disorders
posted by admin in Latest News

Read More
2016
29NOV
Nabriva Announces Terms of Rights Offering
posted by admin in Latest News

Read More
2016
06MAY
venBio Closes $315 Million Life Sciences Venture Capital Fund
posted by admin in Latest News

Read More
2016
27MAR
Baxalta and Precision BioSciences form Global Genome Editing Collaboration in Immuno-Oncology
posted by admin in Latest News

Read More
2016
12FEB
Apellis Completes $47 Million Series D Financing
posted by admin in Latest News

Read More
2015
12AUG
Checkmate Pharmaceuticals Debuts with $20 Million Series A Investment For Development of Novel Immuno-Oncology Product Platform
posted by admin in Latest News

Read More
2015
05AUG
Metacrine Raises $36M in VC Funding, Focuses on Metabolic Diseases
posted by admin in Latest News

Read More
2015
11MAY
Precision BioSciences Lands $26M for Gene-Editing Technology
posted by admin in Latest News

Read More
2014
02JUL
VenBio Scores Again as Genentech Pays $1.7B+ for Seragon Pharma
posted by admin in Latest News

Read More
2014
01JUL
Genentech Announces Definitive Agreement to Acquire Seragon Pharmaceuticals
posted by admin in Latest News

Read More
2014
10JUN
As Its Investors Reap Returns, venBio Aims for a Bigger Second Fund
posted by admin in Latest News

Read More